Lichen or Associated Micro-Organism Compounds Are Active against Human Coronaviruses.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
31 08 2023
Historique:
received: 11 08 2023
revised: 27 08 2023
accepted: 29 08 2023
medline: 29 9 2023
pubmed: 28 9 2023
entrez: 28 9 2023
Statut: epublish

Résumé

(1) Background: Since the emergence of SARS-CoV-2, responsible for the COVID-19 pandemic, efforts have been made to identify antiviral compounds against human coronaviruses. With the aim of increasing the diversity of molecule scaffolds, 42 natural compounds, of which 28 were isolated from lichens and 14 from their associated microorganisms (bacteria and fungi), were screened against human coronavirus HCoV-229E. (2) Methods: Antiviral assays were performed using HCoV-229E in Huh-7 and Huh-7/TMPRSS2 cells and SARS-CoV-2 in a Vero-81-derived clone with a GFP reporter probe. (3) Results: Four lichen compounds, including chloroatranol, emodin, perlatolic acid and vulpinic acid, displayed high activities against HCoV-229E (IC

Identifiants

pubmed: 37766264
pii: v15091859
doi: 10.3390/v15091859
pmc: PMC10536056
pii:
doi:

Substances chimiques

perlatolic acid 0
Antiviral Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Pharmacol Res. 2021 Oct;172:105820
pubmed: 34403732
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
J Fungi (Basel). 2022 Sep 27;8(10):
pubmed: 36294577
Mol Divers. 2021 Aug;25(3):1665-1677
pubmed: 32602074
Science. 2021 Dec 24;374(6575):1586-1593
pubmed: 34726479
N Engl J Med. 2022 Apr 14;386(15):1397-1408
pubmed: 35172054
Biomolecules. 2019 Nov 04;9(11):
pubmed: 31690059
Nat Med. 2022 Jun;28(6):1297-1302
pubmed: 35322239
J Food Drug Anal. 2021 Dec 15;29(4):700-708
pubmed: 35649135
Acta Pharm Sin B. 2020 May;10(5):766-788
pubmed: 32292689
Planta Med. 2014 Jul;80(11):931-5
pubmed: 25029172
Nat Prod Res. 2020 Dec;34(23):3358-3362
pubmed: 30676068
Front Public Health. 2017 Nov 16;5:304
pubmed: 29201864
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Dev Cell. 2021 Dec 6;56(23):3250-3263.e5
pubmed: 34706264
J Nat Prod. 2007 Feb;70(2):316-8
pubmed: 17256903
Rapid Commun Mass Spectrom. 2017 Dec 15;31(23):1993-2002
pubmed: 28873258
New Phytol. 2020 Sep;227(5):1281-1283
pubmed: 32484275
Phytother Res. 2021 Jul;35(7):3447-3483
pubmed: 33590931
N Engl J Med. 2022 Jan 27;386(4):305-315
pubmed: 34937145
Lancet. 2023 Jan 28;401(10373):281-293
pubmed: 36566761
Sci Rep. 2015 Oct 30;5:15839
pubmed: 26514347
PLoS One. 2013 Oct 09;8(10):e76929
pubmed: 24130812
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
Pharm Biol. 2012 Jun;50(6):778-98
pubmed: 22471936
Phytochem Anal. 2015 Jan-Feb;26(1):23-33
pubmed: 25130294
J Nat Prod. 2021 Jan 22;84(1):161-182
pubmed: 33352046
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0158121
pubmed: 34807755
Bioorg Med Chem. 2016 Nov 15;24(22):5823-5833
pubmed: 27687969
J Enzyme Inhib Med Chem. 2020 Dec;35(1):145-151
pubmed: 31724441
Fitoterapia. 2021 Mar;149:104811
pubmed: 33359429
Fitoterapia. 2017 Sep;121:146-151
pubmed: 28705509
Microbiol Res. 2018 Jun;211:1-12
pubmed: 29705201
Nat Rev Mol Cell Biol. 2022 Jan;23(1):21-39
pubmed: 34824452
ChemMedChem. 2012 Dec;7(12):2077-81
pubmed: 23109349
Lancet. 2003 Jun 14;361(9374):2045-6
pubmed: 12814717
Antiviral Res. 2007 May;74(2):92-101
pubmed: 16730806
Front Microbiol. 2022 Sep 29;13:1031204
pubmed: 36246297
N Engl J Med. 2022 Aug 4;387(5):468-470
pubmed: 35857646
Molecules. 2021 Jan 16;26(2):
pubmed: 33467029
J Mol Struct. 2021 Sep 15;1240:130506
pubmed: 33967344
Appl Biochem Biotechnol. 2022 Dec;194(12):6386-6406
pubmed: 35921031
Bioorg Med Chem Lett. 2012 Dec 1;22(23):7060-4
pubmed: 23099095
Phytochemistry. 2018 Jan;145:57-67
pubmed: 29091816
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Molecules. 2017 Feb 28;22(3):
pubmed: 28264516
Antiviral Res. 2018 Feb;150:123-129
pubmed: 29258862
Trends Microbiol. 2017 Jan;25(1):35-48
pubmed: 27743750
PLoS Pathog. 2022 May 19;18(5):e1010498
pubmed: 35587469

Auteurs

Lowiese Desmarets (L)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-Center for Infection and Immunity of Lille (CIIL), F-59000 Lille, France.

Marion Millot (M)

Univ. Limoges, Laboratoire LABCiS, UR 22722, F-87000 Limoges, France.

Marylène Chollet-Krugler (M)

Univ. Rennes, CNRS, ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, F-35700 Rennes, France.

Joël Boustie (J)

Univ. Rennes, CNRS, ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, F-35700 Rennes, France.

Charline Camuzet (C)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-Center for Infection and Immunity of Lille (CIIL), F-59000 Lille, France.

Nathan François (N)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-Center for Infection and Immunity of Lille (CIIL), F-59000 Lille, France.

Yves Rouillé (Y)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-Center for Infection and Immunity of Lille (CIIL), F-59000 Lille, France.

Sandrine Belouzard (S)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-Center for Infection and Immunity of Lille (CIIL), F-59000 Lille, France.

Sophie Tomasi (S)

Univ. Rennes, CNRS, ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, F-35700 Rennes, France.

Lengo Mambu (L)

Univ. Limoges, Laboratoire LABCiS, UR 22722, F-87000 Limoges, France.

Karin Séron (K)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-Center for Infection and Immunity of Lille (CIIL), F-59000 Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH